Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 2;20(1):151.
doi: 10.1186/s12967-022-03350-6.

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy

Affiliations

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy

Lydia Navarrete-Galvan et al. J Transl Med. .

Abstract

Background: The NK cell line NK-92 and its genetically modified variants are receiving attention as immunotherapies to treat a range of malignancies. However, since NK-92 cells are themselves tumors, they require irradiation prior to transfer and are potentially susceptible to attack by patients' immune systems. Here, we investigated NK-92 cell-mediated serial killing for the effects of gamma-irradiation and ligation of the death receptor Fas (CD95), and NK-92 cell susceptibility to attack by activated primary blood NK cells.

Methods: To evaluate serial killing, we used 51Cr-release assays with low NK-92 effector cell to target Raji, Daudi or K562 tumor cell (E:T) ratios to determine killing frequencies at 2-, 4-, 6-, and 8-h.

Results: NK-92 cells were able to kill up to 14 Raji cells per NK-92 cell in 8 h. NK-92 cells retained high cytotoxic activity immediately after irradiation with 10 Gy but the cells surviving irradiation lost > 50% activity 1 day after irradiation. Despite high expression of CD95, NK-92 cells maintained their viability following overnight Fas/CD95-ligation but lost some cytotoxic activity. However, 1 day after irradiation, NK-92 cells were more susceptible to Fas ligation, resulting in decreased cytotoxic activity of the cells surviving irradiation. Irradiated NK-92 cells were also susceptible to killing by both unstimulated and IL-2 activated primary NK cells (LAK). In contrast, non-irradiated NK-92 cells were more resistant to attack by NK and LAK cells.

Conclusions: Irradiation is deleterious to both the survival and cytotoxicity mediated by NK-92 cells and renders the NK-92 cells susceptible to Fas-initiated death and death initiated by primary blood NK cells. Therefore, replacement of irradiation as an antiproliferative pretreatment and genetic deletion of Fas and/or NK activation ligands from adoptively transferred cell lines are indicated as new approaches to increase therapeutic efficacy.

Keywords: Adoptive cell transfer; Fas/CD95; Limitations; Lymphokine activated killer; NK; NK-92; Radiation; Serial killing; Therapeutic efficacy.

PubMed Disclaimer

Conflict of interest statement

Not applicable.

Figures

Fig. 1
Fig. 1
NK-92 cell cytotoxicity and serial killing frequencies of Raji, Daudi and K562 targets. Each colored line/symbol represents %specific release at a different E:T. Dashed lines represent the expected % dead targets if one target was killed by one effector at an E:T. A Raji cells as ‘targets’. B Daudi cells as ‘targets’. C K562 cells as ‘targets’. The three targets were assayed concurrently. The standard deviations for each data point were less than 2% specific 51Cr release. The cytotoxicity towards Raji cells is significantly greater than Daudi and K562 cells (E:T 1:32 linear regression p < 0.01 & p < 0.001, respectively)
Fig. 2
Fig. 2
Effects of irradiation on serial killing. NK-92 cells were irradiated on A the day of experiment or B the day before the experiment and cultured with IL-2. Cytotoxicity was measured after 8 h. The slopes of linear regression for B were 40.4 for the non-irradiated cells and 42.5, 37.6, and 27.5 for the 2.5, 5 and 10 Gy irradiated cells, P < 0.001 for 10 Gy. The KFs for the 1:16 E:Ts are indicated in the two boxes in the middle of the figure. E:Ts are graphed on a log10 scale. [***p-value < 0.001 via regression analysis]
Fig. 3
Fig. 3
Expression of CD95 (Fas) by NK-92 cells and effects of Fas-ligation on their viability. Fas-sensitive Jurkat cells were used as positive controls for Fas expression and death after a day of Fas ligation. Dead cells are indicated by binding of FITC-labeled annexin V to phosphatidyl serine that is externalized in the plasma membranes of dying cells. A Surface expression of Fas/CD95. 1 Expression of Fas by Jurkat cells. 1a Unlabeled cells. 1b Cells labeled with mAb anti-CD95 Fas. 2 Expression of Fas by non-irradiated NK-92 cells. 2a&2b are as indicated for 1a & 1b. 3 Expression of Fas by NK-92 cells irradiated with 10 Gy. 3a&3b are as indicated for 1a &1b. B Induction of death with control IgM or IgM anti-Fas in overnight culture. By Overton subtraction, the conversion from annexin V-low to annexin V-high cells (apoptotic and necrotic) was 52% for Jurkat cells, 5.8% for non-irradiated NK-92 cells, and 9.2% for the irradiated NK-92 cells (*p < 0.05). C Changes in cellular size (forward scatter) in response to irradiation and Fas-ligation. 1 Non-irradiated cells cultured with media, IgM isotype, or anti-Fas IgM. 2 Cells 1 day after 10 Gy irradiation, cultured with media, IgM isotype, or anti-Fas IgM
Fig. 4
Fig. 4
Effects of CD95 (Fas)-ligation on serial killing by non-irradiated and irradiated NK-92 cells. Non-irradiated or 10 Gy irradiated cells were cultured for 1 day with nothing, 1 ug/ml control IgM or IgM anti-Fas. Because K562 cells lack Fas, they were used as tumor ‘target’ cells to prevent addition of anti-Fas-initiated “suicide” to target cell killing by NK-92 cells. Cytotoxic activity towards K562 cells was measured after 8 h. E:T ratios are approximate. A Anti-Fas ligation limited to non-irradiated NK-92 cells. Insert: LU50/1 M non-irradiated NK-92 cell, by treatment. B Anti-Fas ligation of 10 Gy irradiated NK-92 cells. Insert: LU50/1 M irradiated NK-92 cell, by treatment. [***p-value < 0.001 via regression analysis]. KFs A, B The KFs calculated for a 1:1 E:T for A, the non-irradiated control alone, with IgM or with anti-Fas were 0.36, 0.34, and 0.22, respectively. For B, the KFs for the irradiated cells alone, with IgM or with anti-Fas were 0.30, 0.30 and 0.03 respectively. The loss of KF for the irradiated and anti-Fas combination exceeded both additive and synergistic effects estimated based on the losses from single treatments
Fig. 5
Fig. 5
Killing of NK-92 cells by either resting or activated primary blood NK cells. The susceptibility of NK-92 tumor cells to attack by primary peripheral blood NK cells from healthy donors was investigated using NK-92 cells that were either non-irradiated or were irradiated with 10 Gy and then cultured for 1 day. The primary NK cells were either resting or activated by 3 days culture with 1000 u/ml IL-2. Cytotoxicity was measured using 4-h 51Cr-release assays; the gray dashed line reflects the 10% threshold for positive killing. The results illustrated represent concurrent assays made with E:Ts of viable effector NK cells from a single donor SC-0975 and are representative of 4 experiments each with a different donor. A Killing of NK-92 cells by resting primary NK cells. LU50s were excluded for unstimulated NK cells because killing was over 10% for only the highest E:T. B Killing of NK-92 cells by activated primary NK cells. For both bNKs and LAKs, the cytotoxicity towards non-irradiated versus irradiated NK-92 cells was significantly different at the highest E:T (student t-test, *p < 0.03, **p < 0.005). Insert for B LU50/1 M LAK bNK calculated using TruCOUNT™ beads (Gating—Additional file 2: Fig. S1)

Similar articles

Cited by

References

    1. Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Ann Rev Cancer Biol. 2019;3(1):77–103.
    1. Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Investig. 2019;129(9):3499–3510. - PMC - PubMed
    1. Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on “Off-The-Shelf” allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;1:12. - PMC - PubMed
    1. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol. 1995;25(4):1071–1079. - PubMed
    1. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies. PLoS ONE. 2007;2(3):e326. - PMC - PubMed

Publication types